Local life sciences companies like Moderna Inc. and Takeda Pharmaceuticals Inc. are leaning into AI to help employees work ...

Moderna's mRNA platform now features a long list of candidates, and the biotech still has enough cash on hand -- $12.2 ...

Moderna has won U.S. Food and Drug Administration approval for its respiratory syncytial virus vaccine mResvia, ushering in a new era for the ...

Flagship scours labs, research hospitals, and universities for cutting-edge science and builds companies around that science.

The stock's fall snapped a two-day winning streak.

The US Department of Health and Human Services announced Tuesday a contract with Moderna to develop an mRNA vaccine that ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines looks set to continue after London's High Court gave a ...

There have been four human cases of bird flu in the U.S., including three in 2024. Over 130 cow herds in 12 states have seen ...

Some investors might view biotech company Moderna (Nasdaq: MRNA) as a shooting star that shone brightly for a while, then ...

The U.S. government is helping fund Moderna's late-stage trials for its mRNA-based pandemic influenza vaccines as bird flu ...

Moderna stock tumbled in late June after unveiling updated test results for its RSV vaccine. Is MRNA stock now a sell? CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ ...

Moderna Inc. closed $54.02 short of its 52-week high ($170.47), which the company reached on May 24th.